Developer docs
API playgroundTry for free, no card

Search company profiles

Remexian Pharma

Full company profile

uuid00066qp

Namestring
Remexian Pharma
Legal namestring
Remexian Pharma GmbH
Websiteurl
remexian.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Remexian Pharma GmbH is a Ludwigsfelde, Germany-based pharmaceutical wholesaler founded in 2018 that specializes in the importation and wholesale distribution of medical cannabis to German pharmacies. The company sources products from 19 countries globally with a focus on EU-produced cannabis, operating under EU-Good Manufacturing Practice (GMP) and EU-Good Distribution Practice (GDP) standards. Remexian holds wholesale authorization per §52a AMG, narcotics authorization, and manufacturer authorization per §13 AMG, and has secured exclusive German distribution partnerships with six Canadian medical cannabis brands (Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms). The company has captured approximately 14% of Germany's medical cannabis market as of June 2026.

The business model is B2B wholesale distribution: Remexian imports medical cannabis from licensed producers and sells to pharmacies and licensed pharmaceutical wholesalers in Germany under standard 14-day payment terms. Revenue is generated on the margin between import cost and wholesale price. The company is majority-owned (51%) by High Tide Inc. (NASDAQ: HITI), a Canadian cannabis retail company that acquired its controlling stake for €26.4 million in September 2025, implying an enterprise value of approximately €51.8 million. Since acquisition, Remexian has generated $25M in Q1 FY2026 and a record $31.6M in Q2 FY2026 (with 27% gross margins). Operational management is led by Managing Directors Stefan Adomeit and Francesco Baganz, with a team of approximately 10 employees as of late 2024.

Remexian participates in major industry events such as Mary Jane Berlin 2026 and is positioned within Germany's regulated medical cannabis framework as a key import and distribution intermediary. The company's competitive position is anchored by regulatory licensing, exclusive brand partnerships, and an EU-GMP/GDP-compliant cold chain, with strategic integration into High Tide's broader European expansion strategy — including High Tide's first international Canna Cabana retail store opened in Berlin-Mitte in December 2025.

Short descriptiontext

Remexian Pharma GmbH is a German pharmaceutical wholesaler that imports and distributes medical cannabis to pharmacies across Germany, holding 14% market share and exclusive distribution rights to six Canadian cannabis brands. Majority-owned by High Tide Inc. since September 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLudwigsfelde, Germany
HQ citystring
Ludwigsfelde
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis distribution, pharmaceutical wholesale, cannabis import services, EU-GMP compliant supply chain, medical cannabis pharmacy supply
Industry1 code
1Cannabis Wholesale Distribution (Flower, Extracts, Edibles)
CodeCRAOAIAFPrimaryYes
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Wholesale Distribution
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Cannabis Distribution
TypeTransaction Fee
Description

Remexian Pharma generates revenue through the importation and wholesale distribution of medical cannabis products to pharmacies across Germany. The company imports products from licensed producers (primarily from Canada and EU countries) and distributes them to German pharmacies, generating revenue from the margin between import/purchase price and wholesale sale price to pharmacies.

in.investing.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Remexian Pharma GmbH imports and wholesale-distributes medical cannabis to pharmacies across Germany. The company sources products from 19 countries, with particular emphasis on EU-produced cannabis, and holds exclusive German distribution rights for six Canadian medical cannabis brands. It operates under EU-GMP and EU-GDP pharmaceutical quality standards, ensuring consistent availability and quality from manufacturing through delivery to pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Record Q2 FY2026 revenue of $31.6 million with 27% gross margins, more than double the prior quarter
Product overview1 text field

Remexian Pharma operates as a pharmaceutical company specializing in medical cannabis import and wholesale distribution. The company operates as a unified import-distribution platform, sourcing medical cannabis from 19 countries (with emphasis on EU-produced cannabis) and distributing to German pharmacies. Their portfolio includes exclusive distribution partnerships with six Canadian medical cannabis brands (Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms). The company holds approximately 14% of Germany's medical cannabis market and operates under EU GMP and GDP pharmaceutical standards.

Product and service1 record
1Medical Cannabis Import and Wholesale Distribution
CategoryPharmaceutical Wholesale Distribution
Description

Licensed import of medical cannabis from 19 countries and wholesale distribution of standardized medical cannabis products to pharmacies throughout Germany. Operates under EU-GMP and EU-GDP pharmaceutical quality standards across the full supply chain.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with Tribal, a Canadian medical cannabis brand. Tribal's products are introduced to German patients, pharmacies, and healthcare professionals through Remexian's growing distribution network in Germany.

2Highly Dutch Organic
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with Highly Dutch Organic, a Canadian medical cannabis brand. The brand's products are distributed exclusively through Remexian's pharmacy network in Germany.

prnewswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with Weed Me, a Canadian medical cannabis brand. The partnership brings Weed Me's products to the German medical cannabis market via Remexian's distribution infrastructure.

4The Loud Plug
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with The Loud Plug, a Canadian medical cannabis brand, distributing its products exclusively to German pharmacies and patients.

prnewswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with Joi Botanicals, a Canadian medical cannabis brand, bringing its differentiated product portfolio to the German medical cannabis ecosystem.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Remexian Pharma holds an exclusive distribution partnership with Castle Rock Farms, a Canadian medical cannabis brand, with products distributed through Remexian's growing German pharmacy network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remexian Pharma

Pharmaceutical Wholesale Distributionremexian.com

Remexian Pharma GmbH is a German pharmaceutical wholesaler that imports and distributes medical cannabis to pharmacies across Germany, holding 14% market share and exclusive distribution rights to six Canadian cannabis brands. Majority-owned by High Tide Inc. since September 2025.

What Remexian Pharma does

Remexian Pharma GmbH is a Ludwigsfelde, Germany-based pharmaceutical wholesaler founded in 2018 that specializes in the importation and wholesale distribution of medical cannabis to German pharmacies. The company sources products from 19 countries globally with a focus on EU-produced cannabis, operating under EU-Good Manufacturing Practice (GMP) and EU-Good Distribution Practice (GDP) standards. Remexian holds wholesale authorization per §52a AMG, narcotics authorization, and manufacturer authorization per §13 AMG, and has secured exclusive German distribution partnerships with six Canadian medical cannabis brands (Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms). The company has captured approximately 14% of Germany's medical cannabis market as of June 2026.

The business model is B2B wholesale distribution: Remexian imports medical cannabis from licensed producers and sells to pharmacies and licensed pharmaceutical wholesalers in Germany under standard 14-day payment terms. Revenue is generated on the margin between import cost and wholesale price. The company is majority-owned (51%) by High Tide Inc. (NASDAQ: HITI), a Canadian cannabis retail company that acquired its controlling stake for €26.4 million in September 2025, implying an enterprise value of approximately €51.8 million. Since acquisition, Remexian has generated $25M in Q1 FY2026 and a record $31.6M in Q2 FY2026 (with 27% gross margins). Operational management is led by Managing Directors Stefan Adomeit and Francesco Baganz, with a team of approximately 10 employees as of late 2024.

Remexian participates in major industry events such as Mary Jane Berlin 2026 and is positioned within Germany's regulated medical cannabis framework as a key import and distribution intermediary. The company's competitive position is anchored by regulatory licensing, exclusive brand partnerships, and an EU-GMP/GDP-compliant cold chain, with strategic integration into High Tide's broader European expansion strategy — including High Tide's first international Canna Cabana retail store opened in Berlin-Mitte in December 2025.

Remexian Pharma firmographics

Firmographics
Name
Remexian Pharma
Legal name
Remexian Pharma GmbH
Website
https://remexian.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Remexian Pharma GmbH is a German pharmaceutical wholesaler that imports and distributes medical cannabis to pharmacies across Germany, holding 14% market share and exclusive distribution rights to six Canadian cannabis brands. Majority-owned by High Tide Inc. since September 2025.
Ownership category
akta.pro rank

Remexian Pharma industry classification

Industry
Product category
Pharmaceutical Wholesale Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry
Cannabis Wholesale Distribution (Flower, Extracts, Edibles) (CRAOAIAF)

Keywords

  • Medical cannabis distribution
  • Pharmaceutical wholesale
  • Cannabis import services
  • EU-GMP compliant supply chain
  • Medical cannabis pharmacy supply

Where Remexian Pharma is headquartered

Location

Headquarters

HQ city
Ludwigsfelde
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Remexian Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Medical Cannabis Distribution: Remexian Pharma generates revenue through the importation and wholesale distribution of medical cannabis products to pharmacies across Germany. The company imports products from licensed producers (primarily from Canada and EU countries) and distributes them to German pharmacies, generating revenue from the margin between import/purchase price and wholesale sale price to pharmacies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Remexian Pharma product offering

Product offering

Core offering

Remexian Pharma GmbH imports and wholesale-distributes medical cannabis to pharmacies across Germany. The company sources products from 19 countries, with particular emphasis on EU-produced cannabis, and holds exclusive German distribution rights for six Canadian medical cannabis brands. It operates under EU-GMP and EU-GDP pharmaceutical quality standards, ensuring consistent availability and quality from manufacturing through delivery to pharmacies.

Product overview

Remexian Pharma operates as a pharmaceutical company specializing in medical cannabis import and wholesale distribution. The company operates as a unified import-distribution platform, sourcing medical cannabis from 19 countries (with emphasis on EU-produced cannabis) and distributing to German pharmacies. Their portfolio includes exclusive distribution partnerships with six Canadian medical cannabis brands (Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms). The company holds approximately 14% of Germany's medical cannabis market and operates under EU GMP and GDP pharmaceutical standards.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Cannabis Import and Wholesale Distribution Licensed import of medical cannabis from 19 countries and wholesale distribution of standardized medical cannabis products to pharmacies throughout Germany. Operates under EU-GMP and EU-GDP pharmaceutical quality standards across the full supply chain.

Quantifiable outcome

  • Record Q2 FY2026 revenue of $31.6 million with 27% gross margins, more than double the prior quarter

Companies that use Remexian Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Remexian Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Remexian Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • TribalcoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with Tribal, a Canadian medical cannabis brand. Tribal's products are introduced to German patients, pharmacies, and healthcare professionals through Remexian's growing distribution network in Germany.
  • Highly Dutch OrganiccoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with Highly Dutch Organic, a Canadian medical cannabis brand. The brand's products are distributed exclusively through Remexian's pharmacy network in Germany.
  • Weed MecoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with Weed Me, a Canadian medical cannabis brand. The partnership brings Weed Me's products to the German medical cannabis market via Remexian's distribution infrastructure.
  • The Loud PlugcoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with The Loud Plug, a Canadian medical cannabis brand, distributing its products exclusively to German pharmacies and patients.
  • Joi BotanicalscoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with Joi Botanicals, a Canadian medical cannabis brand, bringing its differentiated product portfolio to the German medical cannabis ecosystem.
  • Castle Rock FarmscoreChannel Partner/ Reseller/ Distributor · 11 June 2026Remexian Pharma holds an exclusive distribution partnership with Castle Rock Farms, a Canadian medical cannabis brand, with products distributed through Remexian's growing German pharmacy network.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Remexian Pharma competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Remexian Pharma compliance and trust

Trust signal

Compliance3 records

Remexian Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remexian Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Remexian Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remexian Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remexian Pharma

What does Remexian Pharma do?

Remexian Pharma GmbH imports and wholesale-distributes medical cannabis to pharmacies across Germany. The company sources products from 19 countries, with particular emphasis on EU-produced cannabis, and holds exclusive German distribution rights for six Canadian medical cannabis brands. It operates under EU-GMP and EU-GDP pharmaceutical quality standards, ensuring consistent availability and quality from manufacturing through delivery to pharmacies.

Is Remexian Pharma a public or private company?

Remexian Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Remexian Pharma founded?

Remexian Pharma was founded in 2018. It employs 1 to 10 people.

Where is Remexian Pharma based?

Remexian Pharma is headquartered in Ludwigsfelde, Germany, in the Europe region.

How does Remexian Pharma make money?

One revenue line is on record: medical Cannabis Distribution.

Does Remexian Pharma have an API?

No public API is recorded for Remexian Pharma.

What industry is Remexian Pharma in?

Remexian Pharma's product category is Pharmaceutical Wholesale Distribution. Its primary akta.pro industry code is CRAOAIAF, Cannabis Wholesale Distribution (Flower, Extracts, Edibles). Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsHigh Tide Projects Record Revenue and Growth for Q3 2026 amid Expansion in German Cannabis MarketHigh Tide Inc. announced preliminary guidance for Q3 2026, projecting record revenue of CAD 195–200 million, gross profit of CAD 51–53.5 million, and Adjusted EBITDA of CAD 15.2–16.5 million, exceeding analyst expectations with year-over-year growth ranging from 27% to 55%. The company's growth is driven by Canadian retail operations through its discount club model and rapid scaling of medical cannabis distribution in Germany through its subsidiary Remexian Pharma GmbH, which delivered over 10 tonnes of medical cannabis in the quarter. Full financial results for the quarter ending July 31, 2026, will be released on September 14, 2026.Stock TitanHigh Tide Guides Q3 Revenue to C$195M-C$200MHigh Tide Inc. announced preliminary Q3 2026 guidance for the quarter ended July 31, 2026, expecting record revenue of C$195M-C$200M, gross profit of C$51.0M-C$53.5M, and adjusted EBITDA of C$15.2M-C$16.5M, representing year-over-year growth of at least 30%, 27%, and 43% respectively. The company stated that even the low end of guidance exceeds the highest current analyst estimate across all three metrics. The guidance was driven by Canadian retail returning to positive year-over-year same-store sales in June and July, while Remexian Pharma GmbH achieved a record quarterly distribution of over 10 tonnes of medical cannabis in Germany, up 60% year-over-year.PR NewswireHigh Tide Announces Preliminary Q3 2026 GuidanceHigh Tide Inc. has released preliminary Q3 2026 guidance expecting record revenue, gross profit, and adjusted EBITDA exceeding analyst forecasts. The company also announced a record quarterly distribution of over 10 tonnes of medical cannabis flower through Remexian Pharma GmbH, strengthening its position in the German medical cannabis market. The announcement was made on August 4, 2026, from Calgary, Alberta.FinanzNachrichten.deRaj Grover, CEO von High Tide, beantwortete im Rahmen eines AMA auf Reddit Fragen von AktionärenHigh Tide Inc. CEO Raj Grover conducted the company's fifth Ask Me Anything session on Reddit's r/HighTideInc on July 15, 2026, answering shareholder questions about strategy, operations, and outlook. The AMA followed a busy period for the cannabis retailer, including Q2 2026 financial results, the announced acquisition of Northern Helm, a new $40 million CAD credit facility from BMO, and continued expansion of its German medical cannabis business through majority-owned Remexian Pharma GmbH. The company, which operates the Canna Cabana chain with 229 retail locations, continues its long-standing practice of direct shareholder engagement.Stock TitanHigh Tide CEO Raj Grover Answers Fifth Reddit AMAHigh Tide Inc. CEO Raj Grover answered shareholder questions during his fifth Reddit Ask Me Anything session on July 15, 2026, covering the company's strategy, operations, and outlook. The AMA follows an active period for the company including Q2 fiscal 2026 financial results, the announced acquisition of Northern Helm, approval of C$40 million in new senior credit facilities with BMO, and continued scaling of its German medical cannabis business through majority-owned Remexian Pharma GmbH. The session reflects High Tide's ongoing commitment to direct shareholder engagement through its official subreddit.FinanzNachrichten.deRemexian Pharma, deutsche Tochtergesellschaft von High Tide, präsentiert exklusive Partnerschaften mit kanadischen medizinischen Cannabismarken bei Mary Jane Berlin 2026High Tide Inc.'s majority-owned German subsidiary Remexian Pharma GmbH showcased its exclusive distribution partnerships with six Canadian medical cannabis brands—Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms—at the Mary Jane Berlin 2026 trade show held June 11–14, 2026. The presentation aimed to strengthen Remexian's position as a leading importer and distributor of premium medical cannabis products to German patients and pharmacies in one of the world's fastest-growing medical cannabis markets, where Remexian currently holds a 14% market share. High Tide CEO Raj Grover highlighted the company's procurement capabilities and growing portfolio of exclusive distribution agreements as a significant competitive advantage in Germany's expanding medical cannabis ecosystem.Third NewsHigh Tide's Remexian Pharma Unveils Canadian Cannabis Brands at Mary Jane Berlin 2026High Tide Inc.'s German subsidiary Remexian Pharma GmbH participated in the Mary Jane Berlin 2026 trade show from June 11-14, showcasing exclusive distribution partnerships with six Canadian cannabis brands including Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms. The company positioned itself as a key importer and distributor targeting Germany's growing medical cannabis market, where demand for differentiated, quality products from reputable brands is rising. CEO Raj Grover stated that Remexian's procurement capabilities and expanding portfolio of exclusive agreements are creating a competitive advantage in Germany.PR NewswireHigh Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026High Tide Inc.'s majority-owned German subsidiary Remexian Pharma showcased exclusive distribution partnerships with six Canadian medical cannabis brands—Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, and Castle Rock Farms—at the Mary Jane Berlin 2026 trade show held June 11–14 in Berlin. Remexian holds a 14% share of the German medical cannabis market and is licensed to import from 19 countries, positioning it as a leading importer and distributor in one of the world's fastest-growing medical cannabis markets. The event supported expansion of Remexian's pharmacy network and strengthened relationships with healthcare professionals and industry participants throughout Germany.NewswireHigh Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MMHigh Tide reported record Q2 2026 revenue of $179.3 million, up 30% year-over-year, and adjusted EBITDA of $13.9 million, up 73%. Gross margin reached a record 27%, and the company generated positive net income of $0.6 million. It plans to open 20-30 locations in 2026 and expand into additional European markets.NewswireHigh Tide Announces Purchases of Shares by InsidersHigh Tide Inc. announced that its insiders, led by CEO Raj Grover, acquired 90,882 common shares on the open market between May 6 and May 8, 2026, at an average price of $3.39 per share. The purchases bring insiders to own approximately 8.8% of the company's issued and outstanding shares.